Syndax Pharma (SNDX)

Apr 4, 2025, 4:05 PM EDT - 19 days ago

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Apr 2, 2025, 7:00 AM EDT - 21 days ago

Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum

Mar 3, 2025, 11:46 AM EST - 7 weeks ago

Syndax Pharmaceuticals, Inc. (SNDX) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 7:01 AM EST - 7 weeks ago

Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 25, 2025, 7:00 AM EST - 2 months ago

Syndax Announces Participation in March Investor Conferences

Feb 24, 2025, 7:00 AM EST - 2 months ago

Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025

Feb 10, 2025, 5:42 PM EST - 2 months ago

Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm

Jan 30, 2025, 7:00 AM EST - 2 months ago

Syndax Announces Participation in February Investor Conferences

Jan 15, 2025, 5:34 PM EST - 3 months ago

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes

INCY

Jan 13, 2025, 7:00 AM EST - 3 months ago

Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 7:00 AM EST - 3 months ago

Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference

Dec 9, 2024, 7:30 AM EST - 4 months ago

Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial

Dec 7, 2024, 6:15 PM EST - 4 months ago

Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting

Nov 27, 2024, 7:00 AM EST - 5 months ago

Syndax Announces Participation at the Citi 2024 Global Healthcare Conference

Nov 15, 2024, 6:26 PM EST - 5 months ago

US FDA approves Syndax's blood cancer drug

Nov 15, 2024, 5:29 PM EST - 5 months ago

Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation

Nov 12, 2024, 4:34 PM EST - 5 months ago

Syndax: Fall On NPM1m AML Data Of Revumenib Creates Buy Opportunity

Nov 12, 2024, 7:00 AM EST - 5 months ago

Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib

Nov 5, 2024, 8:39 PM EST - 6 months ago

Syndax Pharmaceuticals, Inc. (SNDX) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 4:01 PM EST - 6 months ago

Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 5, 2024, 9:01 AM EST - 6 months ago

Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024

Nov 5, 2024, 9:00 AM EST - 6 months ago

Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting

Nov 5, 2024, 9:00 AM EST - 6 months ago

Syndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting

Nov 4, 2024, 4:01 PM EST - 6 months ago

Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™

RPRX

Nov 1, 2024, 7:00 AM EDT - 6 months ago

Syndax Announces Participation in November Investor Conferences

Oct 29, 2024, 7:00 AM EDT - 6 months ago

Syndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024

Sep 18, 2024, 5:15 PM EDT - 7 months ago

Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease

INCY

Sep 4, 2024, 7:00 AM EDT - 8 months ago

Foundation Medicine Partners with Syndax to Develop a Companion Diagnostic in Hematology and Support Efforts to Pursue Regulatory Approval for an Assay Based on the FoundationOne®Heme Platform

Aug 12, 2024, 7:00 AM EDT - 9 months ago

Syndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia

Aug 2, 2024, 8:37 AM EDT - 9 months ago

Syndax Pharmaceuticals, Inc. (SNDX) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 4:05 PM EDT - 9 months ago

Syndax Reports Second Quarter 2024 Financial Results and Provides Clinical and Business Update

Jul 29, 2024, 2:51 PM EDT - 9 months ago

FDA Delays Decision on Syndax Leukemia Drug; Stock Sinks

Jul 29, 2024, 7:01 AM EDT - 9 months ago

Syndax Announces PDUFA Action Date Extension for Revumenib NDA for Relapsed or Refractory KMT2Ar Acute Leukemia

Jul 25, 2024, 7:00 AM EDT - 9 months ago

Syndax to Announce Second Quarter 2024 Financial Results and Host Conference Call and Webcast on August 1, 2024

Jun 14, 2024, 7:00 AM EDT - 11 months ago

Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress

Jun 6, 2024, 7:00 AM EDT - 11 months ago

Syndax Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC

Jun 5, 2024, 7:00 AM EDT - 11 months ago

Syndax Announces Participation at the Goldman Sachs 45th Annual Global Healthcare Conference

May 15, 2024, 4:05 PM EDT - 1 year ago

Syndax Pharmaceuticals Appoints Aleksandra Rizo, M.D., Ph.D. to the Board of Directors

May 9, 2024, 7:00 AM EDT - 1 year ago

Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference

May 8, 2024, 4:08 PM EDT - 1 year ago

Syndax Pharmaceuticals, Inc. (SNDX) Q1 2024 Earnings Call Transcript

May 8, 2024, 7:06 AM EDT - 1 year ago

Syndax Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

May 1, 2024, 7:00 AM EDT - 1 year ago

Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024

Apr 10, 2024, 4:05 PM EDT - 1 year ago

Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum

Apr 8, 2024, 7:00 AM EDT - 1 year ago

Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session

Apr 3, 2024, 1:47 PM EDT - 1 year ago

Under-the-radar biotech bets

CRNX MRUS XBI

Mar 28, 2024, 7:00 AM EDT - 1 year ago

Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia

Mar 26, 2024, 4:05 PM EDT - 1 year ago

Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia

Mar 18, 2024, 7:00 AM EDT - 1 year ago

Syndax Announces Appointment of Steven Closter as Chief Commercial Officer

Feb 27, 2024, 9:21 PM EST - 1 year ago

Syndax Pharmaceuticals, Inc. (SNDX) Q4 2023 Earnings Call Transcript